Mologic Signs Agreements with Medisur and Peripal to Distribute PERiPLEX POC Diagnostic in Europe
Published: May 02, 2018
Point-of-care test for detection of infection in patients on peritoneal dialysis available in France, Germany, Italy, The Netherlands, Austria and Switzerland
Bedfordshire, UK, 1st May 2018 -- Mologic Ltd, a developer of powerful, personalised diagnostics to improve the lives of patients, today announced that it has signed agreements with medical technology companies, Medisur and Peripal AG to distribute PERiPLEX®, a rapid point-of-care (POC) test for the detection of infection in patients on peritoneal dialysis (PD). Both companies are specialists in the development and distribution of products which enable patient self-management and will supply PERiPLEX as part of a highly complementary product portfolio in key European markets including France, Germany, Italy, The Netherlands, Austria and Switzerland.
PD is becoming widely accepted as a preferred method for managing end-stage renal disease as it offers greater patient mobility and independence compared to other dialysis options, as well as being gentler to residual kidney function in early-stage disease. Recurring infection, or peritonitis, is a major issue for PD patients especially as there is no effective diagnostic test that can provide early indication of infection. Using current methods, diagnosis of infection can take more than 24 hours, which risks damage to the peritoneal membrane, or the formation of scar tissue, preventing long-term use of PD.
PERiPLEX detects two critical biomarkers of infection in PD waste fluid using a lateral flow immunoassay system and provides a visual result within 10 minutes. A positive result can give PD patients warning of an infection, prompting them to contact their healthcare provider to initiate antibiotic therapy. Earlier identification of infection would enable pre-emptive use of available antibiotics, resulting in improved management of infection and prevention of infection-related damage to the peritoneal membrane.
Mark Davis, co-founder and CEO at Mologic commented: “Establishing a global distribution network is integral to Mologic’s product commercialisation strategy. With the appointment of distributors across Europe we will ensure PERiPLEX is available to more patients, giving them greater choice and the confidence to monitor their dialysis at home. Medisur and Peripal share our mission to improve the lives of patients by bringing diagnostics and treatment closer to home, and with highly complementary product portfolios, we look forward to working together.”
The PERiPLEX technology was developed following a collaborative project with Cardiff University Medical School, funded by the National Institute of Health Research (NIHR).
About Mologic www.mologic.co.uk
Mologic Ltd develops powerful, personalised diagnostics to improve the lives of patients. With a scientific team expert in translating science into practical solutions, the Company delivers technology where it is needed, to improve patient care and quality of life, breaking new ground in exciting fields of research. Mologic is focused on collaboration, partnerships and diversity and its innovative approach has generated an advanced portfolio of accurate and reliable point-of-care diagnostic tools for a variety of conditions, including COPD, diabetes, sepsis, UTIs, malignancies, inflammatory and respiratory conditions, and renal disease.
Led by co-founders Paul Davis, CSO, and Mark Davis, CEO, the Company’s broad range of skills and experience covers services from innovation to manufacture, including molecular engineering, assay and reagent development, clinical evaluation, antibodies, research and IP. Mologic’s low-volume manufacturing facility (ISO13485 certified) enables the business to take on almost any project challenge, irrespective of size, complexity or stage. Through professional partnerships, products have achieved high-volume manufacturing, distribution and regulatory support globally.
Mologic’s interests extend beyond human healthcare, with active programs in agricultural diagnostics, large animal studies and vaccine innovation, successfully translating their advances in patient technology to other sectors.
About Medisur www.medisur.fr
Medisur is a biotechnology company dedicated to the prevention and early diagnosis of disease. The Company specialises in providing pioneering rapid diagnostic test solutions for home use, either by the ‘in-house’ research and development of new solutions, or through the distribution of outsourced products that add value to its portfolio.
Headquartered in Aix-en-Provence, France, Medisur provides a complete customer service to pharmacy, hospital and retailers. It is the first company to launch a complete range of rapid home-use tests in France, with more than 20 parameters such as HIV, fertility and cancer screening.
About Peripal www.peripal.com
Peripal AG, Zürich, Switzerland, was founded in 2015 as a spin-off from ETH (Federal Institute of Technology) in Zurich. The Company was awarded renowned innovation prizes such as de Vigier Prize, Idee Suisse, and Venture ETH.
The Company specialises in medical devices to facilitate home dialysis and has the vision to allow more patients to be treated at home.
Peripal is currently developing and commercialising PeriSafe®, a novel connection device for peritoneal dialysis (PD) patients to make treatment easier and safer for patients around the world. The PeriSafe® system connects the transfer set to the dialysis bag system without any direct manual contact within a protected area.